Literature DB >> 9822096

Effects of therapy with nifedipine GITS or atenolol on mental stress-induced ischemic left ventricular dysfunction.

T C Andrews1, J D Parker, S Jacobs, R Friedman, N Cummings, G MacCallum, F Mannting, G H Tofler, W Carlson, J E Muller, P H Stone.   

Abstract

OBJECTIVES: We sought to determine the effect of nifedipine gastrointestinal therapeutic system (GITS) or atenolol on ischemic left ventricular dysfunction induced by mental stress.
BACKGROUND: The efficacy of conventional antianginal therapy in preventing myocardial ischemia induced by mental stress is unknown.
METHODS: Nifedipine GITS, atenolol and placebo were administered to 15 subjects with stable angina in a double-blind crossover trial. Subjects underwent a series of mental stressors at the end of each treatment. Radionuclide ventriculography was performed at baseline and at peak mental stress. Other measured variables included time to ischemia on exercise treadmill testing, ischemia on 48-h ambulatory electrocardiogram (ECG) monitoring, and resting and mental stress-induced levels of plasma catecholamines, tissue plasminogen activator antigen, plasminogen activator inhibitor-1 and platelet aggregability.
RESULTS: Mental stress resulted in a significant increase in plasma epinephrine and norepinephrine levels during each treatment phase. Atenolol therapy was associated with lower baseline and postmental stress rate-pressure product compared with nifedipine or placebo. Therapy with either nifedipine GITS or atenolol prevented the development of wall-motion abnormalities and the decline in regional ejection fraction (EF) in the segment with the largest deterioration in wall motion during placebo therapy. Both medications prevented the decrease in global EF in subjects who demonstrated at least a 5% fall in global EF on placebo therapy. No therapy exerted a statistically significant benefit on exercise performance or frequency of ischemia during ambulatory ECG monitoring.
CONCLUSIONS: Both nifedipine GITS and atenolol are effective at preventing mental stress-induced wall-motion abnormalities, although the mechanisms may be different.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9822096     DOI: 10.1016/s0735-1097(98)00445-8

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  4 in total

1.  Responses of mental stress-induced myocardial ischemia to escitalopram treatment: background, design, and method for the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment trial.

Authors:  Wei Jiang; Eric J Velazquez; Zainab Samad; Maragatha Kuchibhatla; Carolyn Martsberger; Joseph Rogers; Redford Williams; Cynthia Kuhn; Thomas L Ortel; Richard C Becker; Nicole Pristera; Ranga Krishnan; Christopher M O'Connor
Journal:  Am Heart J       Date:  2011-11-14       Impact factor: 4.749

2.  Association of Mental Stress-Induced Myocardial Ischemia With Cardiovascular Events in Patients With Coronary Heart Disease.

Authors:  Viola Vaccarino; Zakaria Almuwaqqat; Jeong Hwan Kim; Muhammad Hammadah; Amit J Shah; Yi-An Ko; Lisa Elon; Samaah Sullivan; Anish Shah; Ayman Alkhoder; Bruno B Lima; Brad Pearce; Laura Ward; Michael Kutner; Yingtian Hu; Tené T Lewis; Ernest V Garcia; Jonathon Nye; David S Sheps; Paolo Raggi; J Douglas Bremner; Arshed A Quyyumi
Journal:  JAMA       Date:  2021-11-09       Impact factor: 56.272

3.  Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial.

Authors:  Wei Jiang; Eric J Velazquez; Maragatha Kuchibhatla; Zainab Samad; Stephen H Boyle; Cynthia Kuhn; Richard C Becker; Thomas L Ortel; Redford B Williams; Joseph G Rogers; Christopher O'Connor
Journal:  JAMA       Date:  2013-05-22       Impact factor: 56.272

Review 4.  Cardiovascular Imaging of Biology and Emotion: Considerations Toward a New Paradigm.

Authors:  Judith L Meadows; Samit Shah; Matthew M Burg; Steven Pfau; Robert Soufer
Journal:  Circ Cardiovasc Imaging       Date:  2020-08-07       Impact factor: 8.589

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.